The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer

Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib. Herein, we report the first preclinical evaluation of the next-generation ALK TKI, ceritinib (LDK378) in the setting...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Friboulet, Luc, Li, Nanxin, Katayama, Ryohei, Lee, Christian C., Gainor, Justin F., Crystal, Adam S., Michellys, Pierre-Yves, Awad, Mark M., Yanagitani, Noriko, Kim, Sungjoon, Pferdekamper, AnneMarie C., Li, Jie, Kasibhatla, Shailaja, Sun, Frank, Sun, Xiuying, Hua, Su, McNamara, Peter, Mahmood, Sidra, Lockerman, Elizabeth L., Fujita, Naoya, Nishio, Makoto, Harris, Jennifer L., Shaw, Alice T., Engelman, Jeffrey A.
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4068971/
https://ncbi.nlm.nih.gov/pubmed/24675041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0846
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires